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Abstract
In comparison to more differentiated cells, prostate cancer stem- like cells are 
radioresistant, which could explain radio- recurrent prostate cancer. Improvement 
of radiotherapeutic efficacy may therefore require combination therapy. We 
have investigated the consequences of treating primary prostate epithelial cells 
with gamma irradiation and photodynamic therapy (PDT), both of which act 
through production of reactive oxygen species (ROS). Primary prostate epithelial 
cells were cultured from patient samples of benign prostatic hyperplasia and 
prostate cancer prior to treatment with PDT or gamma irradiation. Cell viability 
was measured using MTT and alamar blue assay, and cell recovery by colony- 
forming assays. Immunofluorescence of gamma- H2AX foci was used to quantify 
DNA damage, and autophagy and apoptosis were assessed using Western blots. 
Necrosis and senescence were measured by propidium iodide staining and beta- 
galactosidase staining, respectively. Both PDT and gamma irradiation reduced 
the colony- forming ability of primary prostate epithelial cells. PDT reduced the 
viability of all types of cells in the cultures, including stem- like cells and more 
differentiated cells. PDT induced necrosis and autophagy, whereas gamma 
 irradiation induced senescence, but neither treatment induced apoptosis. PDT 
and gamma irradiation therefore inhibit cell growth by different mechanisms. 
We suggest these treatments would be suitable for use in combination as se-
quential treatments against prostate cancer.
Introduction
When watchful waiting or active monitoring is not an 
option, the most common therapies for localized prostate 
cancer include brachytherapy, radiotherapy, and surgery 
to remove the entire prostate gland (radical prostatectomy) 
[1–4]. All these have side effects, including potential dam-
age to other organs and healthy tissue, incontinence, and 
impotence. Unfortunately, in the case of prostate cancer, 
men are being overtreated due to our inability to 
distinguish between low- risk disease and aggressive cancers 
[5]. As such, there is a need for precise focal therapies 
including cryotherapy, high intensity focused ultrasound 
(HIFU), and photodynamic therapy (PDT) [6]. PDT is 
currently in use for several tumor types, including head 
and neck cancer [7, 8], lung cancer [9], skin cancer, [10, 
11] and more recently, prostate cancer [12]. PDT is emerg-
ing as one of a new series of treatment options that aim 
to focally ablate prostate cancer, thus eliminating the 
tumor(s) with fewer side effects [12, 13]. Since improved 
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screening methods should lead to earlier detection of 
prostate tumors, improved imaging methods will allow 
focal therapy to become increasingly targeted [14]. In 
addition, focal therapies may now be applicable in com-
bination with more standard therapies, such as chemo-
therapeutic agents and radiotherapy [15].
Although PDT is already being used to treat prostate 
cancer in the clinic, the biological basis for its effectiveness 
has not been fully explored, and although there are some 
data on prostate cell lines [16–18], the effect of PDT on 
primary cells cultured from patient samples has not been 
reported. In this study, we used a series of low passage 
primary prostate epithelial cells cultured directly from patient 
tissue, and treated them with a porphyrin- based photosen-
sitizer, which can be conjugated to targeting peptides and 
proteins [19–21]. However, in this in vitro study we were 
simply interested in determining the potential of the core 
photosensitizer to eliminate prostate cancer cells upon light 
irradiation, so the chemical group previously used for con-
jugation was prereacted with a simple amine to prevent 
any nonspecific conjugation occurring during the experi-
ments. Significantly, we also tested the effect of this pho-
tosensitizer drug on the prostate stem- like cell (benign and 
malignant) population that are already known to be radio- 
resistant [22] and are proposed to give rise to secondary 
tumors. Alongside the PDT photosensitizer, we also tested 
the effect of gamma  irradiation on primary prostate epithelial 
cells. Radiotherapy is a widely used treatment for prostate 
cancer, however, 30% of patients treated in this way will 
experience disease recurrence [23]. Whilst we have deter-
mined one mechanism of radio- resistance in primary prostate 
epithelial cells, increased heterochromatin in the stem- like 
cell population, there may be multiple mechanisms. Although 
both therapies produce reactive species, our aim was to 
determine the mechanism of action of each therapy.
Materials and Methods
Culture of primary prostate epithelial cells 
from patient tissue
Benign prostatic hyperplasia (BPH) and prostate cancer 
samples were obtained from TURP (transurethral resection 
of the prostate) and radical prostatectomy operations. 
Prostate epithelial cells were cultured as described [24] 
in stem cell media (SCM). Table 1 shows the samples 
used, including patient and pathology information.
Ethics statement
Patient samples were collected with ethical permission 
from York District Hospital (York) and Castle Hill Hospital 
(Cottingham, Hull) (Ethics Number: 07/H1304/121). Use 
of patient tissue was approved by the Local Research Ethics 
Committees. Patients gave informed consent and all patient 
samples were anonymized.
Selection of cells
Cells were trypsinized, resuspended in SCM and plated 
on collagen I- coated plates following blocking by 0.3% 
heat- inactivated BSA. After 20 min, cells that remained 
unbound were harvested, together with cells from three 
PBS washes; this constituted the committed basal cells 
(CBs) that do not rapidly adhere to collagen I. The bound 
cells were trypsinized, resuspended in MACs buffer 
(PBS/2 μmol/L EDTA/0.5% FCS) and incubated with 
CD133- microbeads. The CD133 microbead kit and MACs 
columns (130- 050- 801, 130- 042- 201, Miltenyi Biotec, 
Surrey, UK) were used to select the CD133+ and CD133− 
cells. The three cell populations obtained were as follows: 
Table 1. Patient samples.
Sample Passage Operation Patient age Diagnosis Hormone status
Benign samples
 H109/11 p3- p4 T 77 Benign \
 H076/11 p3- p4 T 63 Benign \
 H398/14 p4 T 66 Benign \
 Y053/11 p4- p5 T 78 Benign \
 Y068/09 p3 T – Benign \
 H059/11 p3- p5 T 74 Benign \
 H340/13 Lb p4- p5 R 59 Normal \
Cancer samples
 H253/12 La p4 R 71 Cancer Gl7 (4 + 3) Naive
 H263/12 Lb p3 R 58 Cancer Gl7 (3 + 4) Naive
 569 p5 R 67 Cancer Gl8 (3 + 5) Naive
 H316/13 La p3- p6 R 61 Cancer Gl7 (3 + 4) Naive
 H317/13 La p4- p5 R 65 Cancer Gl7 (4 + 3) Naive
 H290/13 Ra p3- p4 R 69 Cancer Gl7 (4 + 3) Naive
R, radical prostatectomy; T, trans- urethral resection of the prostate.
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stem- like cells (SC)—α2β1integrinhi/CD133+, transit- 
amplifying cells (TA)—α2β1integrinhi/CD133−, and com-
mitted basal cells (CB)—α2β1integrinlo. Significantly, the 
SC population is very rare and following selections from 
millions of cells from the total population the yield is a 
few hundred to a few thousand SCs (~0.01%).
Preparation of photosensitizer
5- [Aminobutyl- N- oxycarbonyl)phenyl]phenyl]- 10,15, 
20- tris(N- methyl- 4- pyridinium)porphyrin trichloride was 
prepared as follows:
To a solution of 5- [4- (succinimide- N- oxycarbonyl)
phenyl]- 10,15,20- tris- (4- N- methylpyridimiumyl)porphy-
rin trichloride [20] (50 mg, 0.055 mmol) in dry DMSO 
(5 mL), butylamine (50 mg, 0.68 mmol) was added and 
the mixture stirred at room temperature overnight. Water 
(20 mL) and ammonium hexafluorophosphate were added 
to the mixture until precipitation of the porphyrin was 
observed. The precipitate was collected by filtration and 
redissolved in acetone. Tetrabutylammonium chloride was 
added to the mixture until precipitation of the porphyrin 
was observed, and the precipitate collected by filtration. 
The crude product was purified by precipitation from 
diethyl ether over methanol to yield the product as a 
dark purple solid (34 mg, 71.4%).
UV–vis (H2O): λmax, nm 422, 521, 560, 580, 645. Log 
ε (422 nm) = 5.46. 1H- NMR (DMSO- d6): δ 1.01 (t, 3H, 
J = 8.00 Hz, CH3- CH2), 1.43–1.50 (m, 2H, CH2), 1.54–1.60, 
(m, 2H, CH2), 1.63–1.71 (m, 2H, CH2), 4.72–4.77 (m, 
9H, N- CH3), 8.30–8.40 (m, 4H, 5- o,m- Ph), 8.94–9.23 (m, 
14H, βH and 10,15,20- o- Py), 9.49–9.57 (m, 6H, 10,15,20- 
m- Py). 13C- NMR (DMSO- d6): δ 14.46, (CH3- CH2), 20.35, 
31.97, 48.37 (N- CH3), 115.31, 116.03, 122.54, 126.63, 
132.73 (β- C), 134.73, 135.14, 143.46, 144.78 (β- C), 157.02, 
166.43 (C=O). MS: (ESI) m/z 380 (100[M - 3Cl]2+), 
HRMS: calcd. for C49H44N8O1: 380.1814 found 380.1815.
Gamma irradiation
To irradiate cells, an RS2000 X- Ray Biological Irradiator 
containing a Comet MXR- 165 X- Ray Source (Rad- Source 
Technologies Inc., Suwanee, GA) was used. A dose of 2, 
5, 10, 25, 50 or 75 Gy was administered.
Treatment of cells with photosensitizer
Concentrations of PDT drug between 50–5 μmol/L (Conc 
1–50 μmol/L, Conc 2–37.5 μmol/L, Conc 3–25.0 μmol/L, 
Conc 4–12.5 μmol/L Conc 5–8.75 μmol/L, Conc 
6–5 μmol/L) were used for the MTT assays. Briefly, 800 μL 
of the cells (between 4 × 105 and 1 × 106/mL) was added 
to 200 μL of six dilutions of the photosensitizer in 
12 × 75 mm sterile tubes. The tubes (with tops partially 
open to allow gas exchange) were incubated for 1 h at 
37°C and 5% CO2, after which the cells were washed 
with excess medium to eliminate any unbound photo-
sensitizer. The pellets of cells and porphyrin were resus-
pended in 1 mL medium and 4 × 100 μL of each 
concentration was dispensed into two 96- well plates. One 
plate was irradiated to a dose of 18 J/cm2 using a Paterson 
Lamp BL1000A (Photo Therapeutics Ltd, London, UK—no 
longer in production) equipped with a red filter (GLEN 
S100 367 0134: flat response between ~620 and 642 nm). 
The irradiation dose was determined using a Macam 
Portable Radiometer model R203, Macam Photometrics 
Ltd., Livingston, Scotland, UK. The second plate served 
as a dark control. After light irradiation, the plates were 
returned to the incubator overnight. After 18–24 h, an 
MTT cell viability assay was performed and the results 
expressed as % cell viability versus porphyrin concentra-
tion; an IC50 was determined from the resulting curves. 
Due to a limitation of primary cell cultures (finite number 
of passages), experiments were primarily done as biological 
replicates rather than technical replicates.
MTT assay
Cell viability was determined using an MTT (3- [4, 
5- dimethylthiazol- 2- yl]- 2,5 dipheyltetrazolium bromide) 
colorimetric assay. Briefly, 10 μL of 12 mmol/L MTT 
solution was added to each well and incubated for 1–4 h 
at 37°C to allow MTT metabolism. The crystals were 
dissolved by adding 150 μL of acid- alcohol mixture 
(0.04 mol/L HCl in absolute 2- propanol). The absorb-
ance at 570 nmol/L was measured on a Biotek ELX800 
Universal Microplate Reader, Corgenix Ltd, Peterborough, 
UK and the results expressed relative to control 
values.
Alamar blue assay
Rezasurin sodium salt (Sigma–Aldrich, Cambridge, UK—
R7017) was used to carry out alamar blue assays. A 
25 mmol/L stock was diluted 50- fold to generate a 10× 
working stock. Cells were plated at the stated number 
(1 × 104–2 × 104) per well for whole populations and 
100–300 per well for  selected subpopulations) in 96- well 
plates and incubated with drug (one plate light- irradiated 
and a replica plate as dark control). After 24 h, the alamar 
blue assay to determine cell viability was carried out. 
One- tenth volume of the 10× working stock (20 μL in 
200 μL) was added to cells in a 96- well plate and incu-
bated for 2 h. Fluorescence was measured using a BMG 
Labtech POLARstar OPTIMA microplate reader, BMG 
Labtech, Ortenberg, Germany.
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Clonogenic assay
To determine long- term cell recovery following drug treat-
ment, cells were treated as described above (incubated 
with drug then excess drug washed out), or irradiated 
with gamma irradiation at the stated doses, and cells plated 
at 200–500 cells per well in a 24- well plate (in triplicate), 
with STO feeder cells. Cells were fed every 2 days and 
fixed and stained with crystal violet at 7 days. Colonies 
were counted and plotted as % surviving fraction with 
untreated cells being set at 100% viable.
ROS- Glo H2O2 assay
In order to measure production of H2O2, one of the 
most stable reactive oxygen species and the end product 
of other ROS enzyme reactions [25], the ROS- Glo H2O2 
Assay (Promega G8820, Southampton, UK) was carried 
out. Cells were plated in a 96- well plate (4000–8000 cells 
per well for whole population and 100–300 cells per well 
for selected subpopulations). Drug was incubated with 
the cells for 1 h. Media were changed and one plate 
irradiated (with one as a dark control). Following irradia-
tion, H2O2 substrate from the assay was added and cells 
incubated for 3 h. 50 μL of media was transferred to a 
white plate and combined with the luciferin agent. 
Luminescence was then read in a BMG Labtech POLARstar 
OPTIMA microplate reader. The original plate could sub-
sequently also be used in an alamar blue assay at 24 h. 
These assays were multiplexed when using selected cell 
populations, due to small cell numbers.
Immunofluorescence
Following treatment, cells were seeded onto 8- well col-
lagen I- coated chamber slides for DNA damage detection 
by γH2AX staining. Cells were washed with PBS and 
fixed and stained as described previously [22]. Antibodies 
used were antiphospho- histone H2A.X (Ser139), clone 
JBW301, Millipore, Cat no. 05– 636, 1:1000 and goat 
anti- mouse Alexa Fluor 568, Invitrogen, Paisley, Scotland, 
UK, Cat no. A- 11004, 1:1000. Slides were mounted using 
Vectashield with DAPI (Vector Laboratories, 
Peterborough, UK, Cat no. H- 1200). Images were cap-
tured using a Nikon Eclipse TE300 fluorescent  microscope 
(Nikon, Surrey, UK) with a ×63 oil immersion lens.
Necrosis assay
Cells were incubated with PDT drug for 1 h, then the 
drug- containing media were removed and replaced with 
new media. The cultures were light- irradiated (with control 
dark plates), washed with PBS, then incubated with 
staining solution (Hoechst 33342 (5 μg/mL), Propidium 
Iodide (PI) (2 μg/mL) and RNAse (100 μg/mL) in PBS) 
30 min post light irradiation, for 15 min in the dark at 
37°C. Hoechst- stained blue cells (total cell count) and 
PI- stained red cells (necrotic cells) were visualized with 
a Nikon Eclipse TE300 fluorescent microscope (Nikon, 
Surrey, UK) using a ×10 lens and quantified using Volocity 
software (PerkinElmer, Coventry, West Midlands, UK). 
More than 100 cells per treatment were counted. Data 
were plotted as the percentage of PI- positive cells.
Senescence assay
Primary prostate epithelial cell cultures were irradiated 
with single or multiple doses, as indicated in the Figure, 
and incubated for 48 h before staining for β- galactosidase 
(pH 6.0) to measure senescence. The Senescence 
 β- Galactosidase Staining Kit was used according to manu-
facturer’s instructions (Cell Signaling Technology, Hitchin, 
Herts, UK Cat no. 9860).
Western blotting
Following treatment and light irradiation with the PDT 
drug or gamma irradiation, cell lysates were harvested 
using Cytobuster Protein Extraction Reagent (71009, EMD 
Millipore, Darmstadt, Germany) with protease inhibitors 
(cOmplete, EDTA- free Protease Inhibitor Cocktail Tablets, 
Roche Applied Science, West Sussex, UK). 20 μg extracts 
of cell protein were loaded on 15% SDS- PAGE gels and 
wet- transferred to a PVDF membrane. Antibodies used 
include: rabbit monoclonal antiactin 1:5000 (04- 1040, 
millipore), anti- LC3B 1:3000 (Ab51520, abcam, 
Cambridge, UK), cleaved caspase- 3 (Asp175) 1:1000 
(9661S, Cell Signaling Technology). Secondary antibodies 
used were anti- mouse and anti- rabbit IgG HRP- linked 
1:5000 (Cell Signaling Technology Inc. 7076P2 and 7074S). 
Kaleidoscope protein marker was run on each gel (161- 
0324, Bio- Rad). 1 μmol/L of staurosporine (24 h incuba-
tion) was used as a positive control.
Statistical analysis
MTS and alamar blue assays were performed in triplicate 
and data presented as the % cell viability with percentage 
standard error. IC50 values (Fig. 1B) were calculated from 
graphs of transformed data following application of the 
nonlinear regression (curve fit) that represents the 
log(inhibitor) ‘v’ normalized response (GraphPad Prism 6 
software, La Jolla, CA, USA). For significance calculations, 
the unpaired, nonparametric Mann–Whitney U- test was 
used. The P- values indicating statistical significance are 
displayed (*P < 0.05, **P < 0.01, ***P < 0.001).
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Results
Cell viability of primary prostate epithelial 
cells is reduced by PDT drug treatment but 
not gamma irradiation
Primary epithelial cells cultured from three BPH and three 
prostate cancer (Gleason 7) patient samples were treated 
with a range of concentrations of photosensitizer drug (PDT 
drug), and assessed by MTT assay at 24 h post treatment 
(Fig. 1A). Nonlight- irradiated plates were used as a dark 
control (drug only/no exposure to light). The PDT drug 
with light irradiation was very effective at reducing viability, 
with a 75–85% reduction in BPH cells and an 80–90% 
reduction in cancer cells at the highest concentration. IC50 
values were calculated for each patient sample and these 
ranged between 13–24 μmol/L in BPH samples and 13–
18 μmol/L in cancer samples (Fig. 1A). Cell viability assays 
were also carried out following treatment with a range of 
gamma irradiation doses (0 Gy – 75 Gy) (Fig. 1B). There 
was very little reduction in viability assay with, at most, a 
10–20% reduction. Although initial viability experiments with 
the photosensitizer used the MTT assay, this was changed 
to alamar blue because alamar blue is more sensitive for 
small cell numbers, which was required for later experiments 
with selected cell populations. The MTT and alamar blue 
assays are comparable [26], and so it was not felt necessary 
to repeat the initial MTT assays using alamar blue.
Both PDT drug and gamma irradiation 
treatment reduces colony- forming potential 
of primary prostate epithelial cells, which 
correlates with ROS production
Colony- forming assays were carried out following treatment 
with both PDT drug and gamma- radiation treatment 
(Fig. 2), on four samples per treatment type. In both cases, 
there was a dose- dependent decrease in colony- forming 
ability. With the PDT drug plus light irradiation, concen-
trations of 37.5 μmol/L and above resulted in complete 
absence of colonies (Fig. 2A). For the gamma irradiated 
cells, 10 Gy and higher completely destroyed colony- forming 
ability (Fig. 2B). Individual sample graphs are shown in 
Figure S1, where there is some variation between patients. 
Figure 1. Primary prostate epithelial cells are sensitive to treatment with photodynamic therapy (PDT) drug, but not gamma irradiation when cell 
survival is measured using a cell metabolism assay. (A) Primary prostate epithelial cells from six patients (3× Benign prostatic hyperplasia (BPH) and 3× 
PCa) were treated with several doses of PDT drug and light- irradiated (colored lines), or not light- irradiated (dark control) (gray lines) and measured 
using MTT assay after 24 h (i). IC50 values of all patient samples were calculated (ii). (B) Primary prostate epithelial cells from six patients (3 × BPH and 
3 × PCa) were treated with several different doses of gamma irradiation and measured using alamar blue assay after 24 h.
A
(ii)
(i)
B
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Therefore, even though there was no dramatic cytotoxicity, 
as measured by the cell viability assay following gamma 
irradiation (Fig. 1C), the cells that remained viable had 
nevertheless lost their colony- forming ability.
Since both gamma irradiation and photodynamic thera-
pies produce reactive oxygen species (ROS) we measured 
H2O2 production in both cases (Fig. 2). PDT showed a 
dose- dependent increase in ROS with a maximum of 
600,000 luminescence units (Fig. 2C). Gamma irradiation 
also induced ROS, but with a maximum of 35,000 
luminescence units (Fig. 2D). Taking into account the 
number of cells used in each assay, PDT drug treatment 
induced 10- fold more ROS than gamma irradiation.
PDT drug induces ROS and decreases 
viability of all selected cell subpopulations 
in primary prostate epithelial cell cultures
Previously we had shown that stem- like cells in primary 
prostate epithelial cultures showed gamma irradiation 
Figure 2. Increasing doses of photodynamic therapy (PDT) drug or gamma irradiation results in a reduction and ablation of colony- forming ability in 
primary prostate epithelial cells and an increase in production of Reactive Oxygen Species (ROS). Primary prostate epithelial cells from four patients 
were treated with varying doses of PDT drug (A) or gamma irradiation (B), and the colony- forming ability was assessed after 7 days of growth. Colony- 
forming ability is presented as % surviving fraction. Primary prostate epithelial cells were treated with increasing doses of (C) PDT drug or (D) gamma 
irradiation and the production of ROS was measured using the ROS- Glo assay (Promega).
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resistance when compared with more differentiated transit 
amplifying and committed basal cells [22]. We therefore 
quantified the response of the selected cell populations 
after PDT, to take into account tumor heterogeneity. Since 
the total number of stem- like cells following selection is 
in the 100–1000 range, we used the sensitive alamar blue 
Figure 3. Treatment of selected populations of primary prostate epithelial cells with one dose of photodynamic therapy (PDT) drug results in an 
increase in reactive oxygen species (ROS) production and decrease in cell viability in all populations. Selected populations of primary prostate epithelial 
cells were treated with PDT drug (12.5 μmol/L) and (A) ROS production was measured as well as (B) cell viability. (C) List of cell subpopulations and 
markers.
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cell viability assay rather than the MTT assay [26]. We 
showed the sensitivity of alamar blue to be suitable for 
500 cells per well (Fig. S2). This assay was also multi-
plexed with the ROS- Glo assay to measure H2O2. Following 
PDT, there was an increase in ROS production in all cell 
types (Fig. 3A), which correlated with a decrease in cell 
viability (Fig. 3B).
Differential oxidative stress gene expression 
is induced in cancer versus benign cells
When comparing the different disease states in ROS and 
viability assays there was a noticeable difference between 
cancer and BPH samples (Fig. S3). The cancer samples 
appeared to have both increased reactive oxygen species 
but also increased viability. The difference was observed 
in all cases but was only statistically significant in CB 
cells in the ROS- Glo assay and in TA cells in the cell 
viability assay. In order to investigate this observation 
further, we carried out a reanalysis of our published 
microarray data [27] that compared gene expression in 
stem- like cells (SC) and committed basal cells (CB) in 
both BPH and cancer patient samples. We analyzed 84 
genes that are associated with response to oxidative stress 
(list obtained from the QIAGEN Oxidative Stress RT 
[2] Profiler PCR Arrays). We found that there was sig-
nificant differential gene expression between BPH and 
Cancer (Table 2). Several of the genes that were over-
expressed in benign samples compared to cancer encode 
for antioxidants, and play a role in protecting cells from 
oxidative damage, including conversion of H2O2 to water 
and oxygen (e.g., genes encoding for glutathione per-
oxidases, catalase and a peroxiredoxin, and ATOX1, and 
SCARA3). In addition, MSRA (involved in repairing 
oxidative damage to proteins) and NQO1 (prevents pro-
duction of radical species) were also differentially 
 expressed. Finally, EPAS1, a transcription factor that 
activates genes, including hypoxia responsive genes fol-
lowing reduction in oxygen levels.
Conversely to the genes overexpressed in BPH, several 
genes that were overexpressed in cancer compared to 
benign cells produce ROS, rather than quenching these 
species. For example, NOX4 senses oxygen, produces ROS 
and is associated with tumor growth, and NOX5 and 
NCF2 produce superoxide. APOE and ALOX12 are  involved 
in lipid metabolism, whereas SFTPD is involved in the 
innate immune response to interacting with sugars and 
fats of pathogens. BNIP3 has both antiapoptotic and 
proapoptotic functions. UCP2 is a mitochondrial trans-
porter protein and is involved in control of reactive oxygen 
species derived in the mitochondria, FTH1 encodes for 
the heavy subunit of ferritin, and FOXO4 suppresses 
 expression of hypoxia- induced genes.
PDT drug induces DNA damage, autophagy, 
and necrosis, whereas gamma irradiation 
induces senescence
We had previously observed induction of cytotoxic DNA 
damage in the majority of primary prostate epithelial cells 
following gamma irradiation treatment. After PDT- 
treatment of cells, we were also able to demonstrate DNA 
damage in all cell types (SC, TA, CB) (Fig. 4A).
Since the two therapies showed different results in the 
cell viability assays, but both showed reduction in colony- 
forming ability, we then examined the consequences of the 
treatments on the cells. Firstly, we measured apoptosis in 
one cancer sample and showed that neither PDT (low and 
high conc) nor gamma irradiation (low and high dose) 
resulted in cleaved caspase 3 formation (Fig. 4B(i)). This 
negative result was confirmed in three further patient samples 
(two BPH and two cancer total), where apoptosis was not 
induced by PDT (Fig. 4B(ii)) or gamma irradiation 
(Fig. 4B(iii)) in any sample. We next investigated a potential 
autophagic response following treatment. Here, PDT effec-
tively induced autophagy in one cancer sample (Fig. 4C(i)), 
indicated by reduction in levels of LC3- I and increase in 
levels of LC3- II. In three further samples (two BPH and 
two cancer total) following PDT drug treatment (Fig. 4C(ii)) 
or gamma irradiation (Fig. 4C(iii)) treatment, the PDT drug, 
but not gamma irradiation, induced autophagy.
The PDT- treated cultures revealed considerable cytotoxic-
ity (floating or damaged cells), and were assessed for necrosis 
(Fig. 5A). This was found to be the predominant PDT- 
induced death mechanism in primary prostate epithelial 
Table 2. Oxidative stress genes are differentially expressed in cancer 
and benign cells.
Significance Higher in benign Higher in cancer
<0.01 GPX3 APOE
GPX4 ALOX12
GPX7 NOX4
CAT SFTPD
ATOX1
<0.05 PRDX6 APOE*
TTN NOX5
GCLC BNIP3
MSRA
NQO1
SCARA3
<0.1 GPX2 PXDN
GCLC* NCF2
SQSTM1 NOX4*
EPAS1 UCP2
BNIP3*
FTH1
FOXO4
*Genes that have more than one probe.
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cells. In contrast, the gamma- irradiation- treated cells 
 appeared intact, and neither damaged nor dead. However, 
the cells had flattened and morphologically appeared either 
terminally differentiated or senescent. After treatment with 
single and multiple doses of gamma irradiation, senescence 
in primary prostate epithelial cells was apparent (Fig. 5B). 
This provides an explanation for both the minimal 
reduction in cell survival in the cell viability assay (Fig. 1C) 
and the lack of colony- forming ability (Fig. 2B).
Discussion
Since the established standard of care for prostate cancer 
(gamma irradiation) and the more recent development 
Figure 4. Neither photodynamic therapy (PDT) drug nor gamma irradiation (IR) induces apoptosis, whereas PDT drug induces DNA damage and 
autophagy. (A) Selected primary prostate epithelial cell populations were treated with PDT drug (12.5 μmol/L) and assessed for DNA damage, 
observed as gamma- H2AX foci. Primary prostate epithelial cells from four patients (2× Benign prostatic hyperplasia (BPH) and 2 × PCa) were treated 
with PDT drug or gamma irradiation and a western blot for cleaved caspase 3 was carried out to detect (B) apoptosis or (C) LC3- B to detect autophagy. 
(PDT drug lo = 12.5 μmol/L per hi = 50 μmol/L; Gamma irradiation lo = 2 Gy/hi = 50 Gy).
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of PDT both generate toxic levels of ROS, it may have 
been assumed that they would achieve their therapeutic 
killing in patient cells by the same mechanism. However, 
this study presents evidence to show that PDT and gamma 
irradiation in fact inhibit cell growth by very different 
mechanisms. Our data indicate that irradiation of a pho-
tosensitizing agent with light irradiation (PDT) inhibits 
growth of prostate cells cultured from patient samples, 
which are a clinically relevant model [28]. Since the initial 
cell viability assays showed a significant decrease in the 
primary cells, we also determined long- term recovery of 
cells following treatment, using colony- forming assays. The 
data indicated a dose- dependent reduction in colony for-
mation, where no colonies formed after treatment with 
50 μmol/L of PDT drug in all six primary cell cultures. 
At 37.5 μmol/L and 25 μmol/L there were also no or 
minimal colonies seen in all patient cultures. Interestingly, 
while gamma irradiation (2–75 Gy) did not reduce cell 
viability by more than 20%, there was a significant effect 
of gamma irradiation on colony- forming ability. A potent 
inhibition in colony- forming ability was seen after doses 
of 10 Gy and above.
In order to take into account cell heterogeneity within 
the primary prostate epithelial cell cultures, representative 
of tumor heterogeneity in the patients, we sorted cells 
and treated each cell subpopulation with the PDT drug, 
determining both viability and the production of ROS. In 
other cancers, ROS- quenching enzymes have been impli-
cated as a therapy resistance mechanism in cancer stem 
cells [29], although there is no evidence for this in prostate 
cancer. After first establishing that there was a dose- 
dependent production of H2O2 following addition of the 
PDT drug, the sorted cell populations were tested. We 
were able to multiplex the ROS- Glo assay with the alamar 
blue assay to maximize data from a very small number 
(100s) of cells. In primary prostate epithelial cells we showed 
a correlation between the increase in ROS, and a loss of 
viability in all three cell populations (SC, TA, CB).
After interrogating gene expression microarray data 
comparing stem- like cells and committed basal cells from 
benign and malignant patient tissue [27], we found that 
benign cells expressed genes that are involved in quench-
ing ROS, whereas cancer cells expressed genes encoding 
products that result in production of ROS. It is known 
that cancer cells typically have increased levels of ROS, 
which can act to boost mutation frequency [30–32]. This 
is the logic behind using ROS producing agents as thera-
pies, to increase the amount of ROS production in cancer 
cells over a tolerance- threshold, resulting in increased cell 
death [33]. ROS production in cancer cells is dichotomous, 
since it can be both an inducer of cell death, but can 
also promote cancer cell proliferation [34, 35]. The  increase 
in genes related to ROS quenching in benign cells sug-
gests that these mechanisms are intact in benign cells, 
whereas they will either be absent in cancer cells or over-
ridden by the ROS- producing mechanisms.
Since the photosensitizer induced ROS in all cell sub-
populations from the primary prostate epithelial cultures, 
leading to a reduction in cell viability and colony- forming 
ability, (attributable to induction of necrosis Fig. 5A), this 
drug seems ideally suited for use in prostate cancer treat-
ment. Although both gamma irradiation and PDT induce 
DNA damage, the consequences for the cell are different 
in each case. The induction of autophagy we observed 
(Fig. 4C) is interesting because it can act as a cell- protective 
mechanism [36], but can also lead to cell death [37].
Since the drug in this study can be conjugated to pep-
tides and antibodies, future studies using these compounds 
will investigate improved photosensitizer targeting of pros-
tate cancer cells. Increased targeting of the photosensitizer 
for use in prostate cancer patients can now be attempted 
by binding the drug to a prostate- specific antibody [38]. 
Figure 5. Gamma irradiation induces senescence in primary prostate 
epithelial cells, whereas photodynamic therapy (PDT) drug induces 
necrosis. (A) Primary prostate epithelial cells were treated with PDT drug 
(12.5 μmol/L) and (i) stained for necrotic cells (Propidium iodide positive) 
then (ii) percentage necrotic cells was measured by expressing Propidium 
iodide positive cells relative to total cells (DAPI positive). (B) Primary 
prostate epithelial cells were treated with single or multiple doses of 
gamma irradiation as indicated, incubated for 48 h and stained for beta- 
galactosidase.
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Alternatively, nanoparticle technology could be explored 
to deliver the drug more precisely [39]. Another approach 
is to target the antibody and the drug to the vasculature 
and once light irradiation is directed to the tumor this 
will selectively destroy the tumor vasculature and result 
in cell and tumor death. Promising results using this 
method have already been demonstrated in xenograft 
models of teratocarcinoma and epidermoid carcinoma cells 
[20]. Finally, targeting established hypoxia- associated sur-
face markers may be a strategy to impact the cells in the 
center of the tumor.
As a comparison with the consequences of the photo-
sensitizer treatment, we carried out gamma irradiation 
treatments, which we have previously shown to reduce 
the colony- forming ability of primary prostate epithelial 
cells [22]. Interestingly, this was the caused by senescence 
induction (Fig. 5B) rather than apoptosis, necrosis or 
autophagy [40, 41]. Lack of induction of these cell death 
mechanisms may partially explain why there is frequent 
radio- recurrence of prostate cancer [23].
The absence of apoptosis is potentially unexpected, 
since PDT is known to induce apoptosis in some cell 
lines [42–44]. However, previous studies on the effects 
of chemotherapeutic drugs on primary prostate cells 
compared to established cell lines, showed that apoptosis 
was not induced in the primary cells [28]. In addition, 
after treatment of primary cell cultures with another 
 cytotoxic agent, low- temperature plasma, which also cre-
ates reactive species, cell death was also induced by ne-
crosis and not apoptosis [45].
The basis of the profound differences between PDT 
and gamma irradiation treatments may lie in the mecha-
nisms of ROS generation. Gamma irradiation causes DNA 
damage either directly through chemical modification of 
the DNA molecule or indirectly via the production of 
reactive oxygen species [46]. However, PDT causes DNA 
damage predominantly in an indirect manner through 
production of ROS and cytotoxic intermediate molecules 
in the cytoplasm following light activation [47].
Here, we present evidence in near- patient models that 
both gamma irradiation and PDT induce production of 
reactive oxygen species, but result in differential cytotoxic 
responses. The data imply that a combination of strategies 
would provide a complementary spectrum of cytotoxicity. 
Some studies have already used them in combination [48] 
as part of salvage therapy or pretreatment [15, 49, 50]. 
Due to technical difficulties in accurately delivering both 
radiation and light to patients simultaneously, it is most 
likely that the treatments would be administered sequen-
tially, as shown in other tumor types [51]. By providing 
evidence for mechanisms of cell growth inhibition or cell 
death, there are now sound biological reasons to promote 
the use of such combination therapies in the clinic.
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